Jefferies Raises Price Target on Bristol-Myers Squibb (BMY) Following 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
AstraZeneca (AZN) Shares Decline After Recruitment Paused in Head and Neck Cancer Trial
October 27, 2016 10:58 AM EDT(Updated - October 27, 2016 11:44 AM EDT)
(Updated - October 27, 2016 11:13 and 11:27 AM EDT)
AstraZeneca (NYSE: AZN) declined Thursday, falling over 4% intraday. Chatter suggested weakness was related to a halt in recruitment for its trial evaluating its IO combo in head and neck... More
Stocks dip as earnings pour in, consumer discretionary lags
October 27, 2016 7:34 AM EDTBy Chuck Mikolajczak
NEW YORK (Reuters) - U.S. stocks dipped in a choppy session after the latest round of earnings reports, as a decline in the consumer discretionary sector and interest-rate sensitive stocks outweighed gains in healthcare names.
The S&P 500 healthcare index rose 0.53 percent to help keep the S&P 500 near the unchanged mark, buoyed by strong results and forecasts from Bristol-Myers (NYSE: BMY), up 5.4 percent and Celgene (NASDAQ: CELG), up 6.4 percent. The two drugmakers were the top boosts to the S&P 500.
... MoreBristol-Myers Squibb (BMY) Tops Q3 EPS by 12c; Boosts FY16 Outlook; Approves New $3B Stock Buyback Plan
October 27, 2016 7:00 AM EDTBristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $0.77, $0.12 better than the analyst estimate of $0.65. Revenue for the quarter came in at $4.83 billion versus the consensus estimate of $4.79 billion.
Bristol-Myers Squibb today announced its Board of Directors approved a new $3 billion repurchase... More
Stocks with Implied Volatility Movement
October 27, 2016 5:21 AM EDTBristol-Myers Squibb (NYSE: BMY) implied volatility at upper end of index mean range
... MoreTrading Radar for 10/27: Alphabet (GOOG), Amazon (AMZN), Twitter (TWTR) Ford (F), Baidu.com (BIDU) Report
October 26, 2016 2:46 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Earnings:
Acorda Therapeutics (Nasdaq: ACOR) - no Street consensus
Aetna (NYSE: AET) - consensus EPS $2.03
Agenus (Nasdaq: AGEN) - consensus loss $0.29
Air Products (NYSE:... More
